Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy

Gao, Zhanshan; Zhang, Chuanjie; Xia, Nan; Tian, He; Li, Daoyong; Lin, Jiaquan; Mei, Xifan; Wu, Chao

doi:10.1016/j.actbio.2021.03.018

Cited by 123 publications

(87 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spinal cord injury severely damages the CNS. Gao et al ( 183 ) developed an M2-EV-loaded berberine drug-delivery system that effectively prolonged the duration of berberine and improved its targeting capacity. In addition, it had anti-inflammatory and anti-apoptotic effects by repolarizing Mφ from the M1 to M2 phenotype.…”

Section: Potential Therapeutic Strategiesmentioning

confidence: 99%

The Immuno-Modulation Effect of Macrophage-Derived Extracellular Vesicles in Chronic Inflammatory Diseases

et al. 2021

View full text Add to dashboard Cite

As natural nanocarriers and intercellular messengers, extracellular vesicles (EVs) control communication among cells. Under physiological and pathological conditions, EVs deliver generic information including proteins and nucleic acids to recipient cells and exert regulatory effects. Macrophages help mediate immune responses, and macrophage-derived EVs may play immunomodulatory roles in the progression of chronic inflammatory diseases. Furthermore, EVs derived from various macrophage phenotypes have different biological functions. In this review, we describe the pathophysiological significance of macrophage-derived extracellular vesicles in the development of chronic inflammatory diseases, including diabetes, cancer, cardiovascular disease, pulmonary disease, and gastrointestinal disease, and the potential applications of these EVs.

show abstract

Section: Potential Therapeutic Strategiesmentioning

confidence: 99%

The Immuno-Modulation Effect of Macrophage-Derived Extracellular Vesicles in Chronic Inflammatory Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, EXs with both in ammation suppression and targeting functions are ideal drug carriers. Previous research by our team has con rmed that EXs carrying berberine can effectively reduce the in ammatory response after SCI to promote the recovery of motor function [15].…”

Section: Introductionmentioning

confidence: 79%

“…Therefore, regulating the polarization direction of microglia/macrophages to achieve the balance between M1 microglia/macrophages and M2 microglia/macrophages is a potential treatment strategy for uncontrollable in ammatory responses in SCI [36]. Previous studies have shown that EXs can change the polarization state of M1-type macrophages after being taken up by M1-type macrophages [15,37]. We further found that the ratio of monocytes/macrophages in peripheral blood leukocytes increased signi cantly within 7 d after injury and reached a peak on day 3 (Figure .…”

Section: Discussionmentioning

confidence: 99%

Engineered Exosomes Derived From Primary M2 Macrophages With Anti-inflammatory And Neuroprotective Properties For The Treatment of Spinal Cord Injury.

Zhang

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Uncontrollable inflammation and nerve cell apoptosis are the most destructive pathological response after spinal cord injury (SCI). So, inflammation suppression combined with neuroprotection is one of the most promising strategies to treat SCI. Engineered exosomes with anti-inflammatory and neuroprotective properties are promising candidates for the implementation of this strategies for the treatment of SCI. Results: By combining nerve growth factor (NGF) and curcumin (Cur), we prepared stable engineered exosomes of approximately 120 nm from primary M2 macrophages with anti-inflammatory and neuroprotective properties (Cur@EXs-cl-NGF). Notably, NGF was coupled with EXs by matrix metalloproteinase 9 (MMP9)-cleavable linker to accurately release at the injured site. Through targeted experiments, we found that these exosomes could actively and effectively accumulate at the injured site of SCI mice, which greatly improved the bioavailability of the drugs. Subsequently, Cur@EXs-cl-NGF reached the injured site and could effectively inhibit the uncontrollable inflammatory response to protect the spinal cord from secondary damage; in addition, Cur@EXs-cl-NGF could release NGF into the microenvironment in time to exert a neuroprotective effect against nerve cell damage. Conclusions: A series of in vivo and in vitro experiments showed that the engineered exosomes significantly improved the microenvironment after injury and promoted the recovery of motor function after SCI. We provide a new method for inflammation suppression combined with neuroprotective strategies to treat SCI.

show abstract

“…Protect from SARS-CoV-2 infection by competitively bound to virus against host cells [253] Milk-derived exosomes Anthocyanidins Anti-proliferative and anti-inflammatory in lung cancer [254] Exosomes from breast and colorectal cancer cells Aspirin Cancer therapy [255] Exosomes from MIN-6 cells BAY55-9837 Increase insulin production for type 2 diabetes mellitus [256] Exosomes from macrophages Berberine Spinal cord injury treatment [257] EVs from human umbilical cord mesenchymal stem cells Cannabidiol Increase the therapeutic efficacy of doxorubicin in triple negative breast cancer [258] Exosomes from umbilical cord-derived macrophages Cisplatin Ovarian cancer cells treatment [259] EVs from macrophages…”

Section: Parental Cell Cargo Application Referencementioning

confidence: 99%

Lipid-Based Nanovesicular Drug Delivery Systems

et al. 2021

View full text Add to dashboard Cite

In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should be reliable with a valuable drug profile as well as well-tolerated. Over the past 20 years, nanotechnologies have provided alternative and complementary solutions to those of an exclusively pharmaceutical chemical nature since scientists and clinicians invested in the optimization of materials and methods capable of regulating effective drug delivery at the nanometer scale. Among the many drug delivery carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems as insolubility, biodegradation, and difficulty in overcoming the skin and biological barriers such as the blood–brain one. In this review, the authors discussed the structure, the biochemical composition, and the drug delivery applications of lipid nanovesicular carriers, namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, and extracellular vesicles.

show abstract

Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy

Cited by 123 publications

References 41 publications

The Immuno-Modulation Effect of Macrophage-Derived Extracellular Vesicles in Chronic Inflammatory Diseases

The Immuno-Modulation Effect of Macrophage-Derived Extracellular Vesicles in Chronic Inflammatory Diseases

Engineered Exosomes Derived From Primary M2 Macrophages With Anti-inflammatory And Neuroprotective Properties For The Treatment of Spinal Cord Injury.

Lipid-Based Nanovesicular Drug Delivery Systems

Contact Info

Product

Resources

About